Kidney protective effect of magnesium supplementation on cisplatin-containing chemotherapy in pediatric cancer: a randomized controlled,phase 2 study

Kidney protective effect of magnesium supplementation on cisplatin-containing chemotherapy in pediatric cancer: a randomized controlled,phase 2 study - Mg-rPII

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029215

Enrollment

Registered

2017-09-20

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pediatric oncology

Interventions

Mg+ group: Mg 24-hour continuous infusion (15mEq/m2) Mg- group: without Mg supplementation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: cisplatin-containing courses for the treatment of newly-diagnosed pediatric cancer

Exclusion criteria

Exclusion criteria: heart failure dialysis patient severe infection

Design outcomes

Primary

Measure	Time frame
comparison frequency of nephrotoxicity between the two groups (Mg+ and Mg-)	—

Countries

Japan

Contacts

Public ContactMatsui[ Motohiro

Tokyo Metropolitan Children's Medical center Department of Pediatric Hematology Oncology

motohiro_matsui@tmhp.jp042-300-5111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026